Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study
- PMID: 20035585
- DOI: 10.1089/cap.2008.0146
Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study
Abstract
Aim: The objective of this study was to evaluate predictors of long-term adherence to treatment with methylphenidate (MPH).
Methods: A total of 134 children (ages 4-16) with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) determined by specific protocols, including a semistructured parent interview, Conners' Teacher/Parent Rating Scales, cognitive and learning evaluation, and child self-reports for anxiety and depression, were assessed monthly for up to 36 months. At the end of the study (36 months), three outcomes were evaluated (continuing medication, medication withdrawn due to functional remission, and medication withdrawn for other reasons including poor compliance). Outcomes were first analyzed by mean of the chi-squared test, Mann-Whitney-U test, or t-test, and predictive models were subsequently generated using Cox proportional hazards model analysis. Age, ADHD subtype, co-morbidity, cognitive functioning, side effects, and family and social characteristics were considered as independent variables.
Results: Thirty-six months after starting MPH, 62 children (46%) were still on treatment, 32 (24%) had stopped MPH due to functional remission, and 40 (30%) had suspended MPH for other reasons. Within the last group, 20 suspended for poor compliance, 10 for decrease of efficacy, 5 for side effects, and 5 because they entered in an atomoxetine clinical trial. The presence of associated disorders, younger age, female gender, and not living with both parents were predictors for continuing medication until end of the study (36 months); absence of associated disorders and older age were predictors of discontinuation medication due to functional remission before the end of study, older age, and hyperactive subtype were predictors of discontinuing medication for other reasons.
Conclusion: Clinical outcome of ADHD treatment is heterogeneous: Specific clinical and social predictive parameters for long-term MPH use and compliance can be identified. An accurate tailoring of clinical intervention to the individual child appears crucial for good outcome.
Similar articles
-
Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.Psychiatry Clin Neurosci. 2012 Feb;66(1):53-63. doi: 10.1111/j.1440-1819.2011.02289.x. Psychiatry Clin Neurosci. 2012. PMID: 22250610 Clinical Trial.
-
Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x. Psychiatry Clin Neurosci. 2009. PMID: 19335386 Clinical Trial.
-
Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18. Expert Rev Neurother. 2011. PMID: 21469923
-
Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis.J Clin Psychiatry. 2015 Nov;76(11):e1459-68. doi: 10.4088/JCP.14r09478. J Clin Psychiatry. 2015. PMID: 26646041 Review.
-
A Review of Factors Influencing the Three Phases of Medication Adherence in People with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2019 Aug;29(6):398-418. doi: 10.1089/cap.2018.0153. Epub 2019 May 23. J Child Adolesc Psychopharmacol. 2019. PMID: 31120328
Cited by
-
Heritability and Clinical Characteristics of Neuropsychological Profiles in Youth With and Without Elevated ADHD Symptoms.J Atten Disord. 2022 Sep;26(11):1422-1436. doi: 10.1177/10870547221075842. Epub 2022 Feb 1. J Atten Disord. 2022. PMID: 35102766 Free PMC article.
-
Stimulant Treatment of Young People in the United States.J Child Adolesc Psychopharmacol. 2016 Aug;26(6):520-6. doi: 10.1089/cap.2015.0228. Epub 2016 Mar 16. J Child Adolesc Psychopharmacol. 2016. PMID: 26982632 Free PMC article.
-
The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review.Front Psychiatry. 2022 Feb 9;12:780921. doi: 10.3389/fpsyt.2021.780921. eCollection 2021. Front Psychiatry. 2022. PMID: 35222104 Free PMC article. Review.
-
Factors that Affect the Adherence to ADHD Medications during a Treatment Continuation Period in Children and Adolescents: A Nationwide Retrospective Cohort Study Using Korean Health Insurance Data from 2007 to 2011.Psychiatry Investig. 2017 Mar;14(2):158-165. doi: 10.4306/pi.2017.14.2.158. Epub 2017 Mar 6. Psychiatry Investig. 2017. PMID: 28326113 Free PMC article.
-
A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2021 Apr;31(3):164-178. doi: 10.1089/cap.2020.0104. Epub 2020 Dec 31. J Child Adolesc Psychopharmacol. 2021. PMID: 33395356 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical